Kentucky Clinical Trials Report — June 2026

For Kentuckians considering clinical trial participation, June 2026 presents both urgent opportunities and exciting new avenues for contributing to medical science. Currently, 58 clinical trials across the state are slated to conclude within the next 90 days, meaning interested individuals must act quickly to explore these options before enrollment windows close. This includes 12 studies that are actively seeking healthy volunteers, offering a chance to contribute to research without a specific medical condition.

Time is Running Out: Trials Nearing Conclusion

If you or someone you know is living with certain health conditions, it is crucial to review trials with impending deadlines. Research focusing on various cancers, wound healing, and neurological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Lung cancer
• Ovarian cancer
• Wounds and injuries
• Advanced solid tumor
• Alcohol use disorder
• Ankle sprains
• Alcohol risk behaviors
• Atrial arrhythmia
• Atrial tachycardia
• Attention-deficit/hyperactivity disorder

This is a critical period for individuals who might benefit from these studies or wish to contribute to understanding and treating these conditions. Don't miss the chance to participate in research that could shape future medical care.

New Research Horizons Open Across Kentucky

This month marks a significant expansion in Kentucky's clinical research landscape, with 26 new trials opening for enrollment. This is a substantial increase compared to the 11 new trials that launched in May 2026, indicating a growing momentum in medical innovation across the state. These new studies contribute to the impressive total of 964 clinical trials currently recruiting across 54 cities and 553 research sites statewide.

The new trials span a diverse range of health conditions, with a notable focus on metabolic health, substance use, and pain management. Conditions addressed by these new studies include:

• Obesity
• Cannabis use
• Type 2 diabetes mellitus
• Overweight
• Chronic weight management
• Cocaine use disorder (CUD)
• Critical illness
• Dry eye
• ER-positive HER2-negative breast cancer
• Facial pain

In terms of intervention types, drug trials lead the way, accounting for 20 of the new studies. Device trials, behavioral interventions, and diagnostic tests also represent important areas of new research.

Major Studies Launching with Leading Sponsors

June brings several high-profile Phase 3 trials to Kentucky, sponsored by major pharmaceutical companies. These studies offer participants access to cutting-edge treatments for widespread health challenges and crucial vaccine development.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management and type 2 diabetes.
• Another significant Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy and safety of aleniglipron for weight management.
• For individuals experiencing migraines, Kallyope Inc. is leading two important Phase 3 trials: NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," targeting 1,800 participants, and NCT07674654, a long-term safety study for the same treatment, aiming for 1,000 participants.
• Pfizer is sponsoring NCT07660198, a Phase 3 "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents." This trial will enroll 1,200 participants to evaluate a new pneumococcal vaccine.
• AstraZeneca is also expanding its research into type 2 diabetes with two additional Phase 3 studies: NCT07662213, comparing elecoglipron with oral semaglutide in 1,200 adults with type 2 diabetes and increased cardiovascular risk, and NCT07662044, investigating the efficacy and safety of elecoglipron alone or in combination with dapagliflozin in 800 adults with type 2 diabetes.
• While not a drug trial, the NCT07647354 "Mako-MORE Registry" sponsored by Stryker Orthopaedics is notable for its scale, planning to enroll 950 participants to collect real-world data on joint arthroplasty with Stryker implants, including those using the Mako Robotic-Arm Assisted System.

Geographic Reach: Opportunities Across the Commonwealth

Kentucky's clinical research efforts are broadly distributed, ensuring accessibility for residents across the state. This month, new trials have opened in 10 different cities, with significant concentrations in the state's major metropolitan areas.

• Louisville leads with 13 new trials.
• Lexington follows closely with 12 new trials.
• Bardstown welcomed 3 new trials.
• Edgewood and Bowling Green each saw 2 new trials open.
• Additional new opportunities are available in Hazard, Maysville, Morehead, Mount Vernon, and Owensboro, each with 1 new trial.

This geographic spread highlights that cutting-edge research is not confined to a single region, making participation more convenient for many Kentuckians.

Who Can Participate? Healthy Volunteers and Diverse Demographics

Participation in clinical trials is open to a wide range of individuals. For those without a specific medical condition, there are valuable opportunities to contribute to medical advancements. Of the 26 new trials launched this month, 1 is actively seeking healthy volunteers. Statewide, a total of 81 clinical trials are currently recruiting healthy participants, offering numerous avenues for those interested in supporting medical research.

Clinical trials in Kentucky are designed to be inclusive, with broad eligibility criteria. Of the new trials, 1 includes children as participants, and 1 is female-only. Importantly, 22 of the new trials include older adults, ensuring that research benefits diverse age groups. Industry sponsors are driving a significant portion of this month's new research, with 17 trials sponsored by companies like AstraZeneca, Kallyope Inc., and Pfizer, alongside 9 trials from other types of sponsors.

As June progresses, Kentucky's commitment to advancing medical knowledge remains strong, with a continued focus on both urgent and emerging research needs for patients and healthy volunteers alike.